This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Nuvilex Focused On Positioning Subsidiary, Medical Marijuana Sciences, Inc., To Be A Leading Medical Marijuana Entity By Developing Brain And Pancreatic Cancer Treatments

Stocks in this article: NVLX

SILVER SPRING, Md., Feb. 27, 2013 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology and clinical stage provider of natural products and cell and gene therapy solutions for the treatment of diseases, announced today that it is focused on positioning its subsidiary, Medical Marijuana Sciences, Inc., as a leader among entities in the medical marijuana field by virtue of its goal of using Cannabis constituents in the development of treatments for brain and pancreatic cancer.

Many companies in the medical marijuana arena are technology enterprises concerned with growth and distribution of marijuana or the production of numerous products containing marijuana or forms of its extracts. In contrast, Medical Marijuana Sciences, Inc. is utilizing a number of compounds found in marijuana plants and utilizing them to develop treatments for serious diseases. More specifically, using cannabinoids isolated from Cannabis sativa, Nuvilex's subsidiary will concentrate on the development of treatments for some of the deadliest forms of cancer that have historically shown that they are very difficult to treat with great success. Thus, this effort will initially involve pancreatic cancer and cancers of the brain, particularly glioblastomas. 

Nuvilex's COO, Dr. Gerald Crabtree commented "Nuvilex's "in-house" experience in drug development, particularly in the cancer area, coupled with the knowledge gleaned during the development of our pancreatic cancer treatment, serves as a strong foundation upon which Medical Marijuana Sciences can build treatments, using constituents of Cannabis, for deadly forms of cancer. By pursuing "hard targets" like cancers of the pancreas and brain, Medical Marijuana Sciences can position itself to become a leader among entities involved in the use of marijuana for medicinal purposes."

Nuvilex is a true biotechnology company by virtue of the development of a treatment for advanced, inoperable pancreatic cancer, through its subsidiary Austrianova Singapore (ASPL), involving the use of its proprietary cell encapsulation technology together with the well-known anticancer drug, ifosfamide. On the foundation of very promising results from two independent clinical trials by ASPL, wherein the pancreatic cancer treatment was found to double both the median survival time of patients as well as their one-year-survival rate, preparations are underway for a "late-phase" clinical study that if successful, will ultimately lead to approval by drug regulatory agencies for marketing of Nuvilex's pancreatic cancer treatment.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs